Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

PURPOSE: Romidepsin is a potent histone deacetylase inhibitor (HDI) with activity in T-cell lymphoma. Given preclinical data demonstrating greater induction of gene expression with longer exposures to HDIs, a phase I study of a days 1, 3, and 5 romidepsin schedule was evaluated. A secondary objectiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Amiri-Kordestani, Laleh, Luchenko, Victoria, Peer, Cody J., Ghafourian, Kambiz, Reynolds, James, Draper, Deb, Frye, Robin, Woo, Sue, Venzon, David, Wright, John, Skarulis, Monica, Figg, William D., Fojo, Tito, Bates, Susan E., Piekarz, Richard L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3967244/
https://ncbi.nlm.nih.gov/pubmed/23757352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0095
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados